Compendium of Cancer Genome Aberrations

Changes

HAEM4:Mantle Cell Lymphoma (view source)

Revision as of 16:36, 4 December 2023

338 bytes added ,  16:36, 4 December 2023
no edit summary
Line 1: Line 1:  +
{{DISPLAYTITLE:Mantle Cell Lymphoma}}
 +
 +
 +
<blockquote class='blockedit'>{{Box-round|title=PREVIOUS EDITION|This page from the 4th edition of Haematolymphoid Tumours is being updated. See 5th edition [[HAEM5:Table_of_Contents|Table of Contents]].
 +
}}</blockquote>
 
{{Under Construction}}
 
{{Under Construction}}
 
==Primary Author(s)*==
 
==Primary Author(s)*==
Line 11: Line 16:  
==Cancer Category/Type==
 
==Cancer Category/Type==
   −
* [[Mature B-Cell Neoplasms]]
+
* [[HAEM4:Mature B-Cell Neoplasms]]
    
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
   −
* [[Mantle Cell Lymphoma]]
+
* [[HAEM5:Mantle cell lymphoma]]
    
==Definition / Description of Disease==
 
==Definition / Description of Disease==
Line 54: Line 59:  
***Leukemic involvement is usually a the sign of  disease progression
 
***Leukemic involvement is usually a the sign of  disease progression
 
**Blastoid morphology of the circulating lymphoma cells may mimic acute leukemia
 
**Blastoid morphology of the circulating lymphoma cells may mimic acute leukemia
−
**A leukemic phase with no or minimal lymph node involvement is possible, [[Leukemic Non-Nodal Mantle Cell Lymphoma]]
+
**A leukemic phase with no or minimal lymph node involvement is possible, [[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]
 
***Asymptomatic for long period
 
***Asymptomatic for long period
 
***Splenomegaly
 
***Splenomegaly
Line 185: Line 190:  
*CD10+ MCL more associated with diffuse growth pattern, blastoid/pleomorphic morphology, and BCL6 expression<ref>{{Cite journal|last=J|first=Xu|last2=Lj|first2=Medeiros|last3=A|first3=Saksena|last4=M|first4=Wang|last5=J|first5=Zhou|last6=J|first6=Li|last7=Cc|first7=Yin|last8=G|first8=Tang|last9=L|first9=Wang|date=2017|title=CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases|url=https://pubmed.ncbi.nlm.nih.gov/29545910/|language=en|doi=10.18632/oncotarget.23571|pmc=PMC5837746|pmid=29545910}}</ref>
 
*CD10+ MCL more associated with diffuse growth pattern, blastoid/pleomorphic morphology, and BCL6 expression<ref>{{Cite journal|last=J|first=Xu|last2=Lj|first2=Medeiros|last3=A|first3=Saksena|last4=M|first4=Wang|last5=J|first5=Zhou|last6=J|first6=Li|last7=Cc|first7=Yin|last8=G|first8=Tang|last9=L|first9=Wang|date=2017|title=CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases|url=https://pubmed.ncbi.nlm.nih.gov/29545910/|language=en|doi=10.18632/oncotarget.23571|pmc=PMC5837746|pmid=29545910}}</ref>
 
*CD23: small subset of cases <ref>{{Cite journal|last=S|first=Kumar|last2=Ga|first2=Green|last3=J|first3=Teruya-Feldstein|last4=M|first4=Raffeld|last5=Es|first5=Jaffe|date=1996|title=Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/8878025/|language=en|pmid=8878025}}</ref>
 
*CD23: small subset of cases <ref>{{Cite journal|last=S|first=Kumar|last2=Ga|first2=Green|last3=J|first3=Teruya-Feldstein|last4=M|first4=Raffeld|last5=Es|first5=Jaffe|date=1996|title=Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/8878025/|language=en|pmid=8878025}}</ref>
−
*CD200: May be positive in a subset of SOX11 negative mantle cell lymphomas<ref>{{Cite journal|last=B|first=Espinet|last2=A|first2=Ferrer|last3=B|first3=Bellosillo|last4=L|first4=Nonell|last5=A|first5=Salar|last6=C|first6=Fernández-Rodríguez|last7=E|first7=Puigdecanet|last8=J|first8=Gimeno|last9=M|first9=Garcia-Garcia|date=2014|title=Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry|url=https://pubmed.ncbi.nlm.nih.gov/24352646/|language=en|doi=10.1158/1078-0432.CCR-13-1077|pmc=PMC4488901|pmid=24352646}}</ref>    [[Leukemic Non-Nodal Mantle Cell Lymphoma]]
+
*CD200: May be positive in a subset of SOX11 negative mantle cell lymphomas<ref>{{Cite journal|last=B|first=Espinet|last2=A|first2=Ferrer|last3=B|first3=Bellosillo|last4=L|first4=Nonell|last5=A|first5=Salar|last6=C|first6=Fernández-Rodríguez|last7=E|first7=Puigdecanet|last8=J|first8=Gimeno|last9=M|first9=Garcia-Garcia|date=2014|title=Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry|url=https://pubmed.ncbi.nlm.nih.gov/24352646/|language=en|doi=10.1158/1078-0432.CCR-13-1077|pmc=PMC4488901|pmid=24352646}}</ref>    [[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]
 
*LEF-1: positive in 4 - 9% of mantle cell lymphomas <ref>{{Cite journal|last=Dp|first=O'Malley|last2=Jp|first2=Lee|last3=Am|first3=Bellizzi|date=2017|title=Expression of LEF1 in mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/28038713/|language=en|pmid=28038713}}</ref><ref>{{Cite journal|last=B|first=Sander|last2=L|first2=Quintanilla-Martinez|last3=G|first3=Ott|last4=L|first4=Xerri|last5=I|first5=Kuzu|last6=Jk|first6=Chan|last7=Sh|first7=Swerdlow|last8=E|first8=Campo|date=2016|title=Mantle cell lymphoma--a spectrum from indolent to aggressive disease|url=https://pubmed.ncbi.nlm.nih.gov/26298543/|language=en|pmid=26298543}}</ref>
 
*LEF-1: positive in 4 - 9% of mantle cell lymphomas <ref>{{Cite journal|last=Dp|first=O'Malley|last2=Jp|first2=Lee|last3=Am|first3=Bellizzi|date=2017|title=Expression of LEF1 in mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/28038713/|language=en|pmid=28038713}}</ref><ref>{{Cite journal|last=B|first=Sander|last2=L|first2=Quintanilla-Martinez|last3=G|first3=Ott|last4=L|first4=Xerri|last5=I|first5=Kuzu|last6=Jk|first6=Chan|last7=Sh|first7=Swerdlow|last8=E|first8=Campo|date=2016|title=Mantle cell lymphoma--a spectrum from indolent to aggressive disease|url=https://pubmed.ncbi.nlm.nih.gov/26298543/|language=en|pmid=26298543}}</ref>
 
*Cyclin D1-negative MCL
 
*Cyclin D1-negative MCL
Line 595: Line 600:  
==Links==
 
==Links==
   −
[[Leukemic Non-Nodal Mantle Cell Lymphoma]]
+
[[HAEM5:Leukaemic non-nodal mantle cell lymphoma]]
   −
[[In Situ Mantle Cell Neoplasia]]
+
[[HAEM5:In situ mantle cell neoplasm]]
    
Put your links here (use "Link" icon at top of page)
 
Put your links here (use "Link" icon at top of page)
Line 612: Line 617:     
<nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.
 
<nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.
 +
[[Category:HAEM4]] [[Category:DISEASE]]
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/12485...13270"